Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined With Liposomal Irinotecan in Recurrent or Metastatic Osteosarcoma
NCT07479732Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib, nanoliposomal irinotecan in osteosarcoma (OS), sponsored by Peking University People's Hospital. Started Mar 2026; status: recruiting.
02
Drugs
Rivoceranibnanoliposomal irinotecan
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT07479732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07479732.